Novo Nordisk's Q1 2026 profit rises 65% on strong Wegovy pill launch and 340B provision reversal

Novo Nordisk reported a 65% increase in Q1 2026 operating profit, driven by a provision reversal related to the US 340B Drug Pricing Program and strong sales of its new Wegovy pill for obesity. Adjusted sales excluding the provision reversal fell 4% due to lower prices but were supported by GLP-1 volume growth. The Wegovy pill, launched in January 2026, quickly reached over 2 million prescriptions, marking the strongest GLP-1 launch in the US. Novo Nordisk raised its 2026 outlook, expecting adjusted sales and operating profit growth between -4% and -12% at constant exchange rates, reflecting confidence in GLP-1 product demand and ongoing pipeline progress.